The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The two companies have been involved in recent licensing deals.
MK-6837 has been discontinued, the company discloses.
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
Dispatch Bio’s virus therapy DV-10 enters phase 1.
The company discontinues the Lag3 project in lung cancer.
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
